Highlights of 2024: The year the obesity market took shape The market for anti-obesity medications (AOMs) reached a major milestone in 2024 with global spend exceeding $30Bn for the first time, an over ten-fold increase since 2020
KPV originates from alpha melanocyte-stimulating hormone (-MSH), which itself comes from a precursor protein called proopiomelanocortin (POMC)
Adesanya AW, Lavine MD, Moural TW, Lavine LC, Zhu F, Walsh DB
The contents of this site contain general information and may not reflect current legal developments or address your situation
From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper
